Selective modulation of amyloid‐β peptide degradation by flurbiprofen, fenofibrate, and related compounds regulates Aβ levels

No abstract is available for this paper.

• Publication year

  2009

• Venue

  Journal of Neurochemistry

• Publication date

  2009-11-01

• Fields of study

  Medicine, Chemistry

• Identifiers
  DOI 10.1111/j.1471-4159.2009.06355.xPMID 19702658
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Alzheimer's disease.

  2011cited by this paper
• CHF5074, a novel γ‐secretase modulator, attenuates brain β‐amyloid pathology and learning deficit in a mouse model of Alzheimer's disease

  2009cited by this paper
• Impact of 27-Hydroxycholesterol on Amyloid-β Peptide Production and ATP-Binding Cassette Transporter Expression in Primary Human Neurons

  2009cited by this paper
• The Amyloid Hypothesis of Alzheimer ’ s Disease : Progress and Problems on the Road to Therapeutics

  2009cited by this paper
• P2‐338: Substrate‐targeting gamma‐secretase modulators

  2008cited by this paper
• Efficacy and safety of tarenflurbil in mild to moderate Alzheimer's disease: a randomised phase II trial.

  2008cited by this paper
• Independent Generation of Aβ42 and Aβ38 Peptide Species by γ-Secretase*

  2008cited by this paper
• Treatment of hyperlipidaemia with fenofibrate and related fibrates.

  2008cited by this paper
• Pharmacogenomics and therapeutic prospects in dementia

  2008influential reference
• Amyloid-degrading enzymes as therapeutic targets in Alzheimer's disease.

  2008cited by this paper
• Abeta-degrading enzymes in Alzheimer's disease.

  2008cited by this paper
• ApoE promotes the proteolytic degradation of Abeta.

  2008cited by this paper
• Generation of Abeta38 and Abeta42 is independently and differentially affected by familial Alzheimer disease-associated presenilin mutations and gamma-secretase modulation.

  2008cited by this paper
• Substrate-targeting γ-secretase modulators

  2008influential reference
• Generation of Aβ38 and Aβ42 Is Independently and Differentially Affected by Familial Alzheimer Disease-associated Presenilin Mutations and γ-Secretase Modulation*

  2008cited by this paper
• Molecular genetics of Alzheimer's disease: An update

  2008cited by this paper
• Abeta40 inhibits amyloid deposition in vivo.

  2007cited by this paper
• The role of amyloid beta peptide 42 in Alzheimer's disease.

  2007cited by this paper
• Chronic administration of R-flurbiprofen attenuates learning impairments in transgenic amyloid precursor protein mice

  2007cited by this paper
• In vitro and in vivo profiling of CHF5022 and CHF5074 Two beta-amyloid1-42 lowering agents.

  2007cited by this paper
• Clearance of amyloid-beta by circulating lipoprotein receptors.

  2007cited by this paper
• An update on the amyloid hypothesis.

  2007cited by this paper
• Clearance of amyloid-β by circulating lipoprotein receptors

  2007cited by this paper
• 1-(3′,4′-Dichloro-2-fluoro[1,1′-biphenyl]-4-yl)-cyclopropanecarboxylic Acid (CHF5074), a Novel γ-Secretase Modulator, Reduces Brain β-Amyloid Pathology in a Transgenic Mouse Model of Alzheimer's Disease without Causing Peripheral Toxicity

  2007cited by this paper
• Dominance of Amyloid Precursor Protein Sequence over Host Cell Secretases in Determining β-Amyloid Profiles Studies of Interspecies Variation and Drug Action by Internally Standardized Immunoprecipitation/Mass Spectrometry

  2007cited by this paper
• Insulin degrading enzyme activity selectively decreases in the hippocampal formation of cases at high risk to develop Alzheimer's disease.

  2007cited by this paper
• Aβ40 Inhibits Amyloid Deposition In Vivo

  2007cited by this paper
• The role of amyloid β peptide 42 in Alzheimer's disease

  2007cited by this paper
• Alzheimer's disease

  2006cited by this paper
• Nonsteroidal anti-inflammatory drugs repress beta-secretase gene promoter activity by the activation of PPARgamma.

  2006cited by this paper
• Scaffold of the cyclooxygenase-2 (COX-2) inhibitor carprofen provides Alzheimer gamma-secretase modulators.

  2006cited by this paper
• [Genes in Alzheimer's disease].

  2006cited by this paper
• Alzheimer's disease a century later.

  2006cited by this paper
• Human amyloid-β synthesis and clearance rates as measured in cerebrospinal fluid in vivo

  2006cited by this paper
• The geminal dimethyl analogue of Flurbiprofen as a novel Abeta42 inhibitor and potential Alzheimer's disease modifying agent.

  2006cited by this paper
• Common mechanisms of amyloid oligomer pathogenesis in degenerative disease.

  2006cited by this paper
• Clearance of amyloid-beta in Alzheimer's disease: progress, problems and perspectives.

  2006influential reference
• Genes de la enfermedad de Alzheimer

  2006cited by this paper
• Plasma Aβ in Alzheimer's disease—up or down?

  2006cited by this paper
• The amyloid‐β precursor protein: integrating structure with biological function

  2005cited by this paper
• Diagnosis and Treatment of Alzheimers Disease

  2005cited by this paper
• Diagnosis and Treatment of Alzheimer's Disease

  2005cited by this paper
• Synthesis and biological activity of flurbiprofen analogues as selective inhibitors of beta-amyloid(1)(-)(42) secretion.

  2005cited by this paper
• Dynamic Complexity of the Microglial Activation Response in Transgenic Models of Amyloid Deposition: Implications for Alzheimer Therapeutics

  2005cited by this paper
• Acute treatment with the PPARgamma agonist pioglitazone and ibuprofen reduces glial inflammation and Abeta1-42 levels in APPV717I transgenic mice.

  2005cited by this paper
• Therapeutic potential of nitrate esters of commonly used drugs.

  2005cited by this paper
• Diagnosis and treatment of Alzheimer’s disease

  2005cited by this paper
• Acute treatment with the PPARγ agonist pioglitazone and ibuprofen reduces glial inflammation and Aβ1–42 levels in APPV717I transgenic mice

  2005cited by this paper
• The amyloid-beta precursor protein: integrating structure with biological function.

  2005cited by this paper
• Abeta42 is essential for parenchymal and vascular amyloid deposition in mice.

  2005cited by this paper
• Diverse compounds mimic Alzheimer disease–causing mutations by augmenting Aβ42 production

  2005cited by this paper
• The current status of Alzheimer's disease genetics: what do we tell the patients?

  2004cited by this paper
• Peroxisome Proliferator-Activated Receptor γ Induces a Clearance Mechanism for the Amyloid-β Peptide

  2004cited by this paper
• Selected Non-steroidal Anti-inflammatory Drugs and Their Derivatives Target γ-Secretase at a Novel Site

  2004cited by this paper
• Reduced hippocampal insulin-degrading enzyme in late-onset Alzheimer's disease is associated with the apolipoprotein E-epsilon4 allele.

  2003cited by this paper
• Modulation of β‐amyloid metabolism by non‐steroidal anti‐inflammatory drugs in neuronal cell cultures

  2003cited by this paper
• Evaluation of human peroxisome proliferator-activated receptor (PPAR) subtype selectivity of a variety of anti-inflammatory drugs based on a novel assay for PPAR delta(beta).

  2003cited by this paper
• Sulindac Sulfide Is a Noncompetitive γ-Secretase Inhibitor That Preferentially Reduces Aβ42 Generation*

  2003cited by this paper
• Nonsteroidal Anti-Inflammatory Drugs Can Lower Amyloidogenic Aß42 by Inhibiting Rho

  2003cited by this paper
• Cyclooxygenase-2 Expression by Nonsteroidal Anti-inflammatory Drugs in Human Airway Smooth Muscle Cells: Role of Peroxisome Proliferator-Activated Receptors1

  2003cited by this paper
• Nonsteroidal anti-inflammatory drugs can lower amyloidogenic Abeta42 by inhibiting Rho.

  2003cited by this paper
• A Chemical Switch Regulates Fibrate Specificity for Peroxisome Proliferator-activated Receptor α (PPARα) VersusLiver X Receptor*

  2003cited by this paper
• Nonsteroidal anti-inflammatory drugs and peroxisome proliferator-activated receptor-gamma agonists modulate immunostimulated processing of amyloid precursor protein through regulation of beta-secretase.

  2003cited by this paper
• NSAIDs and enantiomers of flurbiprofen target γ-secretase and lower Aβ42 in vivo

  2003influential reference
• Sulindac sulfide is a noncompetitive gamma-secretase inhibitor that preferentially reduces Abeta 42 generation.

  2003cited by this paper
• Reduced Hippocampal Insulin-Degrading Enzyme in Late-Onset Alzheimer's Disease Is Associated with the Apolipoprotein E-ε4 Allele

  2003cited by this paper
• NSAIDs and enantiomers of flurbiprofen target gamma-secretase and lower Abeta 42 in vivo.

  2003cited by this paper
• Nonsteroidal Anti-Inflammatory Drugs and Peroxisome Proliferator-Activated Receptor-γ Agonists Modulate Immunostimulated Processing of Amyloid Precursor Protein through Regulation of β-Secretase

  2003cited by this paper
• Highly conserved and disease‐specific patterns of carboxyterminally truncated Aβ peptides 1–37/38/39 in addition to 1–40/42 in Alzheimer's disease and in patients with chronic neuroinflammation

  2002cited by this paper
• Pharmacological analysis of wild-type alpha, gamma and delta subtypes of the human peroxisome proliferator-activated receptor.

  2002cited by this paper
• The Amyloid Hypothesis of Alzheimer's Disease: Progress and Problems on the Road to Therapeutics

  2002cited by this paper
• Therapeutic potential of the

  2002cited by this paper
• Reduced Hippocampal Insulin-Degrading Enzyme in Late-Onset Alzheimer’s Disease Is Associated with the Apolipoprotein E- (cid:1) 4 Allele

  2002cited by this paper
• Pharmacological analysis of wild-type α, γ and δ subtypes of the human peroxisome proliferator-activated receptor

  2002cited by this paper
• Selective inhibition of Abeta42 production by NSAID R-enantiomers.

  2002influential reference
• Immunohistochemical localization of neprilysin in the human cerebral cortex: inverse association with vulnerability to amyloid beta-protein (Abeta) deposition.

  2001cited by this paper
• Reduced neprilysin in high plaque areas of Alzheimer brain: a possible relationship to deficient degradation of beta-amyloid peptide.

  2001cited by this paper
• Nonsteroidal antiinflammatory drugs and the risk of Alzheimer's disease.

  2001cited by this paper
• Biochemical characterization of the gamma-secretase activity that produces beta-amyloid peptides.

  2001cited by this paper
• Immunohistochemical localization of neprilysin in the human cerebral cortex: inverse association with vulnerability to amyloid β-protein (aβ) deposition

  2001cited by this paper
• A subset of NSAIDs lower amyloidogenic Aβ42 independently of cyclooxygenase activity

  2001influential reference
• Determination of fenofibric acid in human plasma using automated solid-phase extraction coupled to liquid chromatography.

  2000cited by this paper
• The PPARs: from orphan receptors to drug discovery.

  2000cited by this paper
• Inflammation and Alzheimer's disease.

  2000cited by this paper
• Semiquantitative analysis of amyloid beta peptides using a combination of immunoprecipitation and matrix-assisted laser desorption ionization/ time-of-flight-mass spectrometry.

  1999cited by this paper
• Nonsteroidal anti-inflammatory drug use and Alzheimer-type pathology in aging

  1998cited by this paper
• Glial‐Neuronal Interactions in Alzheimer's Disease: The Potential Role of a ‘Cytokine Cycle’ in Disease Progression

  1998cited by this paper
• Risk of Alzheimer's disease and duration of NSAID use

  1998cited by this paper
• Insulin-degrading Enzyme Regulates Extracellular Levels of Amyloid β-Protein by Degradation*

  1998cited by this paper
• Peroxisome proliferator-activated receptors alpha and gamma are activated by indomethacin and other non-steroidal anti-inflammatory drugs.

  1997cited by this paper
• Peroxisome Proliferator-activated Receptors α and γ Are Activated by Indomethacin and Other Non-steroidal Anti-inflammatory Drugs*

  1997cited by this paper
• Risk of Alzheimer's disease and duration of NSAID use

  1997cited by this paper
• Degradation of Amyloid β-Protein by a Metalloprotease Secreted by Microglia and Other Neural and Non-neural Cells*

  1997cited by this paper
• Anti‐Inflammatory Drugs in the Fight against Alzheimer's Disease a

  1996cited by this paper
• Nonsteroidal anti-inflammatory drugs in Alzheimer's disease

  1995cited by this paper
• The disordered neuronal cytoskeleton in Alzheimer's disease.

  1992cited by this paper
• INTERNATIONAL SOCIETY FOR NEUROCHEMISTRY

  1976cited by this paper
• Nonsteroidal Antiinflammatory Drugs and the Risk of Alzheimer's Disease

  year unknowncited by this paper

• Targeting of the PI3 K/AKT/GSK3β Pathway in Parkinson's Disease: A Therapeutic Blueprint

  2025cites this paper
• Decrypting the Possible Mechanistic Role of Fenofibrate in Alzheimer's Disease and Type 2 Diabetes: The Truth and Mystery

  2025cites this paper
• Flavonoids and fibrate modulate apoE4-induced processing of amyloid precursor protein in neuroblastoma cells

  2023cites this paper
• Modulation of γ-Secretase Activity by a Carborane-Based Flurbiprofen Analogue

  2021cites this paper
• Pharmacological manipulation of cGMP and NO/cGMP in CNS drug discovery.

  2019cites this paper
• Recent Advances in Neuroinflammation Therapeutics: PPARs/LXR as Neuroinflammatory Modulators.

  2016cites this paper
• Pharmacological modulation of dietary lipid-induced cerebral capillary dysfunction: Considerations for reducing risk for Alzheimer’s disease*

  2016cites this paper
• Fenofibrate reduces amyloidogenic processing of APP in APP/PS1 transgenic mice via PPAR‐α/PI3‐K pathway

  2014cites this paper
• Modulatory activity of soluble beta amyloid on HPA axis function in rats.

  2014cites this paper
• Nitrate Chimeras: A New Class of Disease Modifying Agents for the Treatment of Alzheimer's Disease

  2014cites this paper
• Modulating nitric oxide signaling in the CNS for Alzheimer's disease therapy.

  2013cites this paper
• The Proton-Pump Inhibitor Lansoprazole Enhances Amyloid Beta Production

  2013cites this paper
• Design and synthesis of a novel series of bicyclic heterocycles as potent γ-secretase modulators.

  2012cites this paper
• Inhibition of amyloidogenesis by nonsteroidal anti-inflammatory drugs and their hybrid nitrates.

  2011cites this paper
• The Roles of GxxxG Motif and γ -Secretase Components in APP Processing

  2011cites this paper
• Inflammation-associated risk factors for Alzheimer s disease and dementia

  2010cites this paper
• Acute Effect on the Aβ Isoform Pattern in CSF in Response to γ-Secretase Modulator and Inhibitor Treatment in Dogs

  2010cites this paper
• Neuroinflammation, oxidative stress and the pathogenesis of Alzheimer's disease.

  2010cites this paper
• NO‐flurbiprofen reduces amyloid‐β, is neuroprotective in cell culture, and enhances cognition in response to cholinergic blockade

  2009cites this paper
• The Roles of GxxxG Motif and Gamma-Secretase Components in APP Processing

  2009cites this paper